

# PROVIDER Update



CONTRACTUAL | MAY 13, 2022 | UPDATE 22-376 | 4 PAGES

## Stay Current with the Injectable Medication HCPCS/DOFR Crosswalk Reference Table – 2nd Quarter 2022

### Use the updates for dates of service on and after July 19, 2022

On April 11, 2022, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective July 19, 2022, are listed on pages 2-3 of this Provider Update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 19 new injectable medications to be added to the DOFR crosswalk.
- 7 updates and changes to injectable medication procedure codes.

#### Additional information

Relevant sections of Health Net's\* provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to Health Net's provider website at [provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com) > *Provider Library* under Quick Links, or go directly to [providerlibrary.healthnetcalifornia.com](http://providerlibrary.healthnetcalifornia.com).

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at [provider\\_services@healthnet.com](mailto:provider_services@healthnet.com) within 60 days, by phone or through the Health Net provider website as listed in the right-hand column.

#### Go to the online COVID-19 alerts page for info about COVID-19 vaccines!

At [provider.healthnet.com](http://provider.healthnet.com) > *COVID-19 Updates* > *Health Net Alerts*, you will find information about COVID-19 vaccines. This includes COVID-19 vaccine coverage details, how to enroll to administer the COVID-19 vaccine, and COVID-19 vaccine reporting and coding requirements. Also, access key tips you can use to help talk with and answer questions from your patients about the COVID-19 vaccine, especially those who are hesitant to receive it.

#### THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Supports (CS) Providers
- Enhanced Care Management (ECM) Providers

#### LINES OF BUSINESS:

- IFP (Ambetter from Health Net)
  - HMO/HSP
  - EPO
  - PPO
- Employer Group
  - HMO/POS/HSP
  - EPO
  - PPO
- Medicare Advantage (HMO/PPO) (Wellcare By Health Net)
- Cal MediConnect (Los Angeles/San Diego)
- Medi-Cal
  - Kern
  - Los Angeles
    - Molina
  - Riverside
  - Sacramento
  - San Bernardino
  - San Diego
  - San Joaquin
  - Stanislaus
  - Tulare

#### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)

**Ambetter from Health Net IFP**

**EnhancedCare PPO** – 844-463-8188

**Health Net Employer Group HMO, POS, HSP, PPO, & EPO** – 800-641-7761

**Ambetter from Health Net IFP**

**CommunityCare HMO, PPO, PureCare HSP, & PureCare One EPO** – 888-926-2164

**Medicare (individual & employer group) (Wellcare By Health Net)** – 800-929-9224

**Cal MediConnect**

Los Angeles County – 855-464-3571

San Diego County – 855-464-3572

**Medi-Cal (including CS and ECM providers)** – 800-675-6110

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com)

#### PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)

\*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Adbry™	Tralokinumab-ldrm injection, for subcutaneous use	Therapeutic injection	
J3590	Carvykti™	Ciltacabtagene autoleucel suspension for intravenous infusion	Therapeutic injection	
J3590	Enjaymo™	Sutimlimab-jome injection, for intravenous use	Therapeutic injection	
J3490	Evusheld™	Tixagevimab 150 Mg/1.5ml & Cilgavimab 150 Mg/1.5ml IM Soln	Therapeutic injection	Immunization
J3590	Kimmtrak®	Tebentafusp-tebn IV soln 100 mcg/0.5m	Therapeutic injection	Chemotherapy <sup>1</sup>
J3490	Leqvio®	Inclisiran injection, for subcutaneous use	Therapeutic injection	
90619	Menquadfi™	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use	Therapeutic injection	Immunization
J3590	Releuko™	Filgrastim-ayow inj soln 300 mcg/ml	Self-injectable	Chemotherapy Adjunctive <sup>1</sup>
J3590	Ryplazim®	Plasminogen, human-tvmh	Therapeutic injection	
J3590	Skytrofa™	lonapegsomatropin-tcgd for injection, for subcutaneous use	Self-injectable	Growth hormone
J3590	Susvimo™	Ranibizumab injection) for intravitreal use (Ocular Implant)	Therapeutic injection	
J3590	Tezspire™	Tezepelumab-ekko injection, for subcutaneous use	Therapeutic injection	
J3590	Tivdak™	Tisotumab vedotin-tftv for injection 40 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Vabysmo™	Faricimab-svoa intravitreal inj 6 mg/0.05ml	Therapeutic injection	
90697	Vaxelis™	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use	Therapeutic injection	Immunization

<b>J0248</b>	Veklury®	Remdesivir, 1 mg	Therapeutic injection	
<b>J3490</b>	Voxzogo™	Vosoritide for injection, for subcutaneous	Self-injectable	
<b>J3590</b>	Vyvgart™	Efgartigimod alfa-fcab injection, for intravenous use	Therapeutic injection	
<b>J3490</b>	Xipere™	triamcinolone acetonide injectable suspension, for suprachoroidal use	Therapeutic injection	

### Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>J9071</b>	Cyclophosphamide	Injection, cyclophosphamide, (AuroMedics), 5mg, 10 mg	Replaces C9087
<b>C9091</b>	Fyarro™	Sirolimus protein-bound particles for IV	Replaces J3590
<b>J2505</b>	Neulasta® onpro®	6MG/0.6ML Solution J2506 Injection, pegfilgrastim,	Replaces J2506
<b>J9293</b>	Novantrone®	Mitoxantrone hydrochl / 5 MG	No longer Manufactured
<b>S0148</b>	Pegintron®	peginterferon alfa-2b	No longer Manufactured
<b>J9999</b>	Sylatron™	Peginterferon alfa-2b	No longer Manufactured
<b>J3490</b>	Tanzeum™	Albiglutide Injection	No longer Manufactured

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.